Skip to main content
. Author manuscript; available in PMC: 2011 Apr 15.
Published in final edited form as: Int J Cancer. 2010 Apr 15;126(8):1850–1860. doi: 10.1002/ijc.24964

Fig. 5.

Fig. 5

FACS (a) and immunoblot (b) analysis MDA-MB-361/wt and MDA-MB-361/vIII cells treated with the protein synthesis inhibitor cycloheximide (10 µg/mL) showing that EGFRvIII-expressing breast cancer cells have increased stability of CXCR4 protein levels. (b - bottom panel), densitometry measurements of CXCR4 immunoblot results. (c) Immunoblot analysis of lysates from MDA-MB-361 (“361”), BT474, MCF-7, and SKBR3 cells with and without EGFRvIII expression showing that AIP4 and β-arrestin 1/2 are down-regulated in multiple breast cancer cells expressing EGFRvIII. See Supplemental Fig. 6 for an additional β-arrestin 1/2 blot.